Industries

Pharmaceuticals & Diagnostics

Toutes les analyses de Pharmaceuticals & Diagnostics — 1 analyses.

36/100 92Buffett Hold Roche Zen Horizon Framework Deep Dive: A Diagnostics and Pharma Giant Past the Patent Cliff, with a Fair Price and Debated Growth Roche is the global leader in in vitro diagnostics and a top-tier pharmaceutical company in oncology, neurology, and ophthalmology, with family control and CHF-denominated shares. The company has moved past its patent cliff, new medicines have filled an approximately USD 10 billion gap, and the group has returned to +7% constant-currency growth, though a strong Swiss franc has reduced reported growth to only +2% in CHF. Rating Hold: valuation is fair at roughly 16x forward PE with a 3% dividend, 27% below the 2022 high, while growth remains debated and obesity is the largest upside option. Roche Holding AGROG · SWPharmaceuticals & Diagnostics5 juin 2026